标题
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
作者
关键词
-
出版物
Cell Death & Disease
Volume 10, Issue 5, Pages -
出版商
Springer Nature
发表日期
2019-04-25
DOI
10.1038/s41419-019-1568-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition
- (2018) Clare E. Weeden et al. ONCOGENE
- BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL
- (2018) Georgia Greaves et al. CELL DEATH AND DIFFERENTIATION
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
- (2018) Donia M. Moujalled et al. LEUKEMIA
- AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies
- (2018) Sean Caenepeel et al. Cancer Discovery
- The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma
- (2017) Bibhusal Thapa et al. Journal of Thoracic Oncology
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
- (2017) T-C Teh et al. LEUKEMIA
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
- (2017) Delphine Merino et al. Science Translational Medicine
- Combenefit: an interactive platform for the analysis and visualization of drug combinations
- (2016) Giovanni Y. Di Veroli et al. BIOINFORMATICS
- Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
- (2016) J.-N. Gong et al. BLOOD
- Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM
- (2016) Leona Rohrbeck et al. CELL DEATH AND DIFFERENTIATION
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Role of the pro-survival molecule Bfl-1 in melanoma
- (2015) C.K. Hind et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
- (2015) Y. Xiao et al. MOLECULAR CANCER THERAPEUTICS
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo
- (2015) Brandon J. Aubrey et al. Cell Reports
- Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids
- (2015) Kimberley A. Beaumont et al. Jove-Journal of Visualized Experiments
- Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance
- (2014) M N Serasinghe et al. ONCOGENE
- Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells
- (2014) Arnim Weber et al. Translational Oncology
- Structure-guided design of a selective BCL-XL inhibitor
- (2013) Guillaume Lessene et al. Nature Chemical Biology
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel
- (2013) Andreas Behren et al. Pigment Cell & Melanoma Research
- BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
- (2013) Rizwan Haq et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
- (2012) D. Wroblewski et al. CARCINOGENESIS
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1
- (2012) Daniela Senft et al. PLoS One
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
- (2011) K. M. Lucas et al. CLINICAL CANCER RESEARCH
- Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization
- (2011) Haiming Dai et al. JOURNAL OF CELL BIOLOGY
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria
- (2011) Fabien Llambi et al. MOLECULAR CELL
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-737 synergizes with Bortezomib to kill melanoma cells
- (2011) S. N. Reuland et al. Biology Open
- A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy
- (2010) W J Placzek et al. Cell Death & Disease
- RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway
- (2009) Angela M. Keuling et al. PLoS One
- Melanocytes: From Morphology to Application
- (2009) A. Santiago-Walker et al. SKIN PHARMACOLOGY AND PHYSIOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
- (2008) Mark S. Cragg et al. JOURNAL OF CLINICAL INVESTIGATION
- BH3 Mimetic ABT-737 and a Proteasome Inhibitor Synergistically Kill Melanomas through Noxa-Dependent Apoptosis
- (2008) Leslie A. Miller et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax
- (2008) J. I. Fletcher et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More